Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
22.8 EUR | 0.00% | +3.64% | 0.00% |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
Jul. 12 | Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market | RE |
Sales 2024 * | 42.98B 39.43B | Sales 2025 * | 52.79B 48.43B | Capitalization | 856B 785B |
---|---|---|---|---|---|
Net income 2024 * | 11.94B 10.95B | Net income 2025 * | 16.59B 15.22B | EV / Sales 2024 * | 20.4 x |
Net Debt 2024 * | 20.15B 18.48B | Net Debt 2025 * | 16.12B 14.79B | EV / Sales 2025 * | 16.5 x |
P/E ratio 2024 * |
71.1
x | P/E ratio 2025 * |
51.1
x | Employees | 43,000 |
Yield 2024 * |
0.55% | Yield 2025 * |
0.63% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 week | +3.64% | ||
Current month | +2.70% | ||
1 month | +6.54% | ||
3 months | +22.58% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 04-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-16 | 22.8 | 0.00% | 0 |
24-07-15 | 22.8 | -8.80% | 0 |
24-07-12 | 25 | +11.61% | 1,250 |
24-07-11 | 22.4 | -0.88% | 0 |
24-07-10 | 22.6 | +2.73% | 0 |
Delayed Quote Deutsche Boerse AG, July 16, 2024 at 03:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.99% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+13.58% | 244B | |
+5.15% | 234B | |
+16.25% | 226B | |
+14.63% | 177B | |
+1.08% | 165B |
- Stock Market
- Equities
- LLY Stock
- LLY0 Stock